Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
Open Access
- 1 January 2015
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 11, 143-51
Abstract
Alpha-1 antitrypsin (AAT) deficiency remains an underrecognized genetic disease with predominantly pulmonary and hepatic manifestations. AAT is derived primarily from hepatocytes; however, macrophages and neutrophils are secondary sources. As the natural physiological inhibitor of several proteases, most importantly neutrophil elastase (NE), it plays a key role in maintaining pulmonary protease–antiprotease balance. In deficient states, unrestrained NE activity promotes damage to the lung matrix, causing structural defects and impairing host defenses. The commonest form of AAT deficiency results in a mutated Z AAT that is abnormally folded, polymerized, and aggregated in the liver. Consequently, systemic levels are lower, resulting in diminished pulmonary concentrations. Hepatic disease occurs due to liver aggregation of the protein, while lung destruction ensues from unopposed protease-mediated damage. In this review, we will discuss AAT deficiency, its clinical manifestations, and augmentation therapy. We will address the safety and tolerability profiles of AAT replacement in the context of patient outcomes and cost-effectiveness and outline future directions for work in this field.Keywords
This publication has 81 references indexed in Scilit:
- Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α 1 -Antitrypsin: Interim ResultsHuman Gene Therapy, 2011
- Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production MethodHuman Gene Therapy, 2010
- Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometryRespiratory Research, 2010
- Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized studyBMC Clinical Pharmacology, 2010
- Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyProceedings of the National Academy of Sciences, 2009
- Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic FibrosisJournal of Biological Chemistry, 2008
- Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokineticsThorax, 2006
- Hepatic gene therapy: Efficient retroviral-mediated gene transfer into rat hepatocytes in vivoSomatic Cell and Molecular Genetics, 1993
- Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with EmphysemaNew England Journal of Medicine, 1987
- Mutation of Antitrypsin to AntithrombinNew England Journal of Medicine, 1983